Berkeley Newswire

Berkeley Newswire

Comprehensive Real-Time News Feed for Berkeley, CA.

Results 1 - 20 of 31 for "u:biospace.com" in Berkeley, CA

  1. Bay Area's Carmot Lands $240M+ R&D Tie-Up With Biotech Giant AmgenRead the original story w/Photo

    Dec 5, 2017 | BioSpace

    Carmot Therapeutics , announced today that it has entered into a multi-year drug discovery collaboration and licensing agreement with Amgen . As part of the agreement, Carmot will apply its proprietary lead-identification technology, Chemotype Evolution, to discover and advance novel drug leads intended for the treatment of Parkinson's disease and other selected disease areas.

    Comment?

  2. Meet the 5 Bay Area Biotech Entrepreneurs Under 30Read the original story w/Photo

    Nov 14, 2017 | BioSpace

    Every year, Forbes creates lists of "30 Under 30" leaders in various industries who are under the age of 30. This year, one of their lists is 30 Under 30 in healthcare . Five of those selected are with Bay Area biotech companies.

    Comment?

  3. Meet the 4 Biotechs That are Disrupting HealthcareRead the original story w/Photo

    Nov 13, 2017 | BioSpace

    It's not always easy to see when a company is a "disruptor," which is to say, that it causes a paradigm shift in how an industry operates. A classic example is Amazon , which definitely disrupted bookselling, then retail in general, publishing, and just about every industry it touches.

    Comment?

  4. Daiichi Sankyo's Tumor Drug Meets Primary Endpoint in Late-Stage StudyRead the original story w/Photo

    Oct 30, 2017 | BioSpace

    Daiichi Sankyo announced today that the pivotal phase 3 placebo-controlled ENLIVEN study of pexidartinib met its primary endpoint of tumor response as measured by tumor size reduction in patients with symptomatic tenosynovial giant cell tumor where surgical resection is potentially associated with worsening functional limitation or severe morbidity. A comprehensive evaluation of the benefit/risk for TGCT based on the totality of the pexidartinib program is now underway and will guide next steps.

    Comment?

  5. GNI Announces Clearance Of Investigational New Drug (IND) By FDA For...Read the original story

    Oct 9, 2017 | BioSpace

    GNI Group Ltd., announced that GNI USA, Inc. , the wholly-owned subsidiary of GNI Group, had received U.S. FDA clearance on September 29 for the Investigational New Drug application for F351 for U.S. clinical trials in the treatment of liver fibrosis. F351 is an orally available, small molecule drug candidate with potential to treat liver fibrosis associated with chronic liver diseases.

    Comment?

  6. Avillion Appoints As Chief Business OfficerRead the original story

    Oct 2, 2017 | BioSpace

    Avillion LLP, a drug development company focused on the co-development and financing of late-stage pharmaceutical candidates, from post proof-of-concept Phase 2 and Phase 3 to market approval, announces that it has appointed Kathryn J. Gregory, MBA, as Chief Business Officer . Ms Gregory will be based in the US and will be focused on expanding the clinical co-development opportunities for Avillion.

    Comment?

  7. Novartis AG Launches R&D Center on UC Berkeley's Campus to Tackle 'Undruggable' DiseasesRead the original story

    Sep 27, 2017 | BioSpace

    Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer New Novartis-Berkeley Center for Proteomics and Chemistry Technologies combines Novartis' expertise in chemical biology with Berkeley's expertise in covalent chemoproteomics Basel, Switzerland, September 28, 2017 - Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and are considered "undruggable."

    Comment?

  8. Bay Area's XOMA Licenses Out Another Part of Its Pipeline to Novartis AG in $31 Million DealRead the original story

    Aug 24, 2017 | BioSpace

    In a separate agreement, XOMA has granted Novartis a license to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment of cardiovascular disease. Under these agreements, XOMA will receive $31 million in upfront payments, including a $5 million equity investment, and is eligible to receive significant pre- and post-commercialization milestone payments plus tiered high-single to mid-double-digit royalties on net sales of gevokizumab.

    Comment?

  9. Bayer HealthCare Expansion Brings New Jobs to the Bay AreaRead the original story

    Aug 16, 2017 | BioSpace

    August 17, 2017 By Mark Terry , BioSpace.com Breaking News Staff After two years of construction, Bayer HealthCare recently held a ribbon-cutting ceremony to open its new quality assurance control facility in West Berkeley, Calif. The new building is three stories and 80,000 square feet.

    Comment?

  10. XOMA Reports Second Quarter 2017 Financial ResultsRead the original story

    Aug 8, 2017 | BioSpace

    BERKELEY, Calif., Aug. 08, 2017 -- XOMA Corporation , a pioneer in the discovery and development of therapeutic antibodies, today announced its second quarter 2017 financial results and recent business highlights. "We made significant progress executing our new strategy to create long-term value for shareholders in the second quarter," stated Jim Neal, Chief Executive Officer of XOMA.

    Comment?

  11. Integrated DNA Technologies Launches First Cas9 Enzyme That...Read the original story

    Jul 31, 2017 | BioSpace

    Integrated DNA Technologies today announced the launch of the first Cas9 enzyme variant that extensively reduces off-target effects in CRISPR genome editing without compromising on-target activity. The Alt-RA S.p. HiFi Cas9 Nuclease 3NLS enzyme is a recombinant S. pyogenes Cas9 mutant that improves specificity while maintaining a high editing efficiency similar to wild-type Cas9.

    Comment?

  12. CMC Biologics Enters Into Development And Manufacturing Agreement With Trellis BioscienceRead the original story

    Jul 26, 2017 | BioSpace

    Development of Trellis' monoclonal antibody using CMC Biologics' proprietary CHEF1A Expression Platform and Multi-column Continuous Chromatography Technology Bothell, Washington, Berkeley, California, and Menlo Park, California, USA- July 25, 2017 - CMC ICOS Biologics, Inc., a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, and Trellis Bioscience LLC, a private, venture-funded therapeutic antibody company, announced today they have entered into a manufacturing agreement for the process development and production of two of Trellis' monoclonal antibodies .

    Comment?

  13. Humabs Biomed And UC Berkeley Announce Publication Of Data For Novel...Read the original story

    Jul 17, 2017 | BioSpace

    BELLINZONA, Switzerland & BERKELEY, Calif.-- --Humabs BioMed SA, a leading Swiss antibody therapeutics company, and the University of California, Berkeley today announced the publication of data with an antibody-based assay, developed by Humabs, to detect and differentiate Zika virus infections from other flaviviruses such as dengue in the leading peer-reviewed journal, Proceedings of the National Academy of Sciences . The article is titled, "Antibody-based assay discriminates Zika virus infection from other flaviviruses."

    Comment?

  14. Syneron Candela Completes Previously Announced Transaction With Funds ...Read the original story

    Jul 17, 2017 | BioSpace

    Syneron Medical Ltd. , a leading global non-surgical aesthetic device company, today announced the successful completion of its acquisition by an affiliate of funds advised by Apax Partners for $11.00 per share in cash in a transaction valued at approximately $400 million. The transaction was announced on April 3, 2017 and received approval from Syneron Candela's shareholders on June 15, 2017.

    Comment?

  15. Smelling Your Food First Can Make You Fat, UC Berkeley Study RevealsRead the original story

    Jul 6, 2017 | BioSpace

    You may not realize it but your sense of smell may influence just how much weight you gain when you eat food. A new study by the University of California Berkeley suggests that the odor of the food that people eat may play a key role in how the body is able to deal with calories.

    Comment?

  16. Caribou Biosciences Appoints Ph.D. As Chief Scientific OfficerRead the original story

    Jul 5, 2017 | BioSpace

    Caribou Biosciences, Inc., a leading genome engineering company, announced today that Steven B. Kanner, Ph.D. has joined the Company as Chief Scientific Officer. Dr. Kanner brings more than 25 years of experience in drug discovery and development and will lead Caribou's research and development of new applications for its gene editing technology.

    Comment?

  17. Protocol First Selected By The Leukemia & Lymphoma Society (LLS)...Read the original story

    Jun 29, 2017 | BioSpace

    Protocol First , a software-as-a-service EDC data management company, founded April 2015 in Berkeley, California, has been selected by The Leukemia & Lymphoma Society for the Beat AMLA Master Trial Initiative, a clinical trial in acute myeloid leukemia. The Beat AML Master Trial is among the first cancer clinical trials to be led by a nonprofit health organization and takes personalized medicine to new heights in an effort to bring innovative therapies to one of the deadliest blood cancers.

    Comment?

  18. Biodesy Appoints As Chief Executive OfficerRead the original story

    Jun 28, 2017 | BioSpace

    Biodesy, Inc., the next-generation protein analysis company, today announced that Dominique Bridon, PhD, has been appointed Chief Executive Officer and a member of the board of directors, effective immediately. Dr. Bridon brings more than 27 years of executive and scientific leadership experience to the Biodesy team.

    Comment?

  19. Ximbio Release: Why CRISPR Should Be Welcomed When It Comes To Research ToolsRead the original story

    Jun 28, 2017 | BioSpace

    CRISPR has changed the gene-editing landscape, and there are big questions being debated, explains Melanie Hardman, Founder of Ximbio, On both sides of the Atlantic, patent lawyers are debating who should have intellectual property rights over the most exciting and most flexible gene-editing technique yet devised for eukaryotic DNA. The CRISPR/Cas9 system is a type of immune-response mechanism used by some archaea and bacteria.

    Comment?

  20. Ocular Therapeutix Names Bristol-Myers Squibb-Novartis AG Vet as New CEORead the original story

    Jun 22, 2017 | BioSpace

    Antony Mattessich to Assume CEO Role in September 2017 and Joins Board; Amar Sawhney to Transition to Executive Chairman of the Board )--Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that in line with Ocular's strategic plan and growth objectives, Antony Mattessich will succeed Dr. Amar Sawhney as Chief Executive Officer, on or before September 30, 2017. Until that time, Dr. Sawhney will continue to serve as Chief Executive Officer and Chairman of the Board of Directors, and will then transition to an Executive Chairman role.

    Comment?

Berkeley Job Listings
View or post Berkeley job listings on Topix.
Berkeley Real Estate
News, listings, and foreclosures in Berkeley from Topix.
Berkeley Mortgages
Find mortgage rates in Berkeley on Topix.